Afecta Pharmaceuticals Announces Grant of U.S. Patent
IRVINE, CA / ACCESSWIRE / March 23, 2021 / Afecta Pharmaceuticals, a company focused on developing drugs that modulate key pathways that drive disease processes associated with immune disorders, neurological dysfunction and cancers, announced that the United States Patent and Trademark Office has granted a patent on March 9, 2021 for a class of novel compounds that inhibit the CCL5/RANTES pathway. The patent, U.S. Patent No. 10,940,132, discloses compounds and methods for treating conditions with increased CCL5/RANTES activity. This pathway is a key driver of severe inflammation associated with many diseases.
Afecta Pharmaceuticals Enters Into Research Collaboration Agreement With UCI
Afecta Pharmaceuticals has entered into a research collaboration agreement with the University of California, Irvine (UCI) to interrogate promising drug molecules for the treatment of advanced melanoma using the PharmetRx® AI-based drug discovery and development platform.
Afecta Pharmaceuticals CEO to Present at 2019 SF BioHealth Impact Forum
IRVINE, Calif., January 30, 2019, Afecta Pharmaceuticals, Inc., today announced that its Founder and Chief Executive Officer Bruce Kovacs, MD will present at the BioHealth Impact Forum in San Francisco on Thursday, February 7, 2019. Dr. Kovacs will provide an overview of Afecta's breakthrough product development portfolio for serious skin diseases during the "Groundbreaking Discoveries & Innovations" session.
Afecta Pharmaceuticals CEO to Present at 2018 Outsourced Pharma Conference
Afecta Pharmaceuticals CEO will be speaking as a panelist at the 2018 Outsourced Pharma Conference in San Diego, CA on Aug 21-22, 2018.
Afecta Pharmaceuticals CEO to Present at 2018 Drug Delivery West Conference
Afecta Pharmaceuticals CEO will be speaking as a panelist for "Physician Perspectives on Current and Future Drug Delivery Needs" as part of the 2018 Drug Delivery West Conference in San Francisco, CA on May 21-22, 2018.